Floatz logo

11 assets in Sjogren Syndrome

Therapeutic assets addressing Sjogren Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Rituximab
Sjogren Syndrome
Peking Union Medical College HospitalP4BB (64)
Belimumab
Sjogren Syndrome
Peking Union Medical College HospitalP4B (63)
Diluent
Sjogren Syndrome
Instituto de Oftalmología Fundación Conde de ValencianaP3B (60)
Bcma-Cd19 Ccar T Cells
Sjogren Syndrome
Peking University People's HospitalP2CCC (53)
Car-Nk Cell
Sjogren Syndrome
Bangdong GongP1/2CCC (48)
Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy
Sjogren Syndrome
Beijing Boren HospitalP1CC (43)
Cabozantinib
Sjogren Syndrome
National Cancer Institute (NCI)P1CC (43)
Ipilimumab
Sjogren Syndrome
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Sjogren Syndrome
National Cancer Institute (NCI)P1CC (43)
her2bbζ/cd19t+ t cells
Sjogren Syndrome
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Early P1C (39)
Blood, Whole
Sjogren Syndrome
University Hospital, BrestN/AD (30)